INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER
Clinical trials for INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy aims to keep bladder cancer at bay
Disease control Recruiting nowThis phase 3 trial tests a gene therapy called nadofaragene firadenovec against simply watching and waiting in people with intermediate-risk non-muscle invasive bladder cancer. The study will enroll 454 participants who have had a tumor removed. The goal is to see if the gene the…
Matched conditions: INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 08:00 UTC
-
New bladder cancer drug shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with a type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder through a catheter. The main goals are to find the safest dose and see if people can toler…
Matched conditions: INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC